Navigation Links
iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs

NASHUA, N.H., March 12 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early detection of cancer, today announced that John DeLucia has joined iCAD as the Vice President of Quality Assurance and Regulatory Affairs, reporting to iCAD President and CEO Ken Ferry. Mr. DeLucia brings more than 25 years of medical device, in-vitro diagnostics and biomedical research experience to this key management position. Mr. DeLucia has significant experience working with the FDA and other global regulatory authorities, and will be responsible for navigating iCAD through several anticipated FDA milestones. His expertise includes managing and directing regulatory submissions, compliance, clinical studies, quality assurance and laboratory services for medical device and clinical diagnostic products.

"We are delighted to have John join iCAD's management team," said Ken Ferry. "We are confident that John's experience and successful track record with the FDA and other regulatory agencies will be of tremendous value to iCAD as we execute on our growth strategy and bring new products to market."

"I am especially pleased to be joining iCAD at this exciting time, as we have an opportunity to bring several compelling cancer screening technologies through the regulatory process and on to commercialization," said Mr. DeLucia. "I look forward to being an integral part of iCAD's success."

Prior to joining iCAD, Mr. DeLucia served as Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Z-Tech Medical Inc., a medical device company that developed a novel bioimpedance breast scanning detection system. Mr. DeLucia was responsible for directing and managing clinical trials, global regulatory submissions, facility quality operations and reporting, and regulatory compliance activities.

Before joining Z-Tech Medical Inc., Mr. DeLucia was Vice President of Regulatory Affairs, Clinical Affairs and Quality Assurance at Microsulis Americas, Inc., a medical device company that manufactures endometrial ablation systems for gynecological markets worldwide. Prior to that, he served as the Division Vice President of Quality Assurance for the Critical Care Division at Smiths Medical Critical Care, which develops and manufactures Class I and II anesthesia, respiratory, needle safety devices, and a wide variety of critical care devices. During his career he has also worked at companies such as ACMI Corporation, Genzyme, C.R. Bard and Pfizer.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 1800 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit

For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at

For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at

For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release, including but not limited to, statements about the Company's confidence or strategies or expectations about revenues, results of operations, timing of regulatory approval of products or market opportunities, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
2. Haemonetics(R) Appoints Peter Allen as Chief Marketing Officer
3. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
4. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
5. Spectral appoints Anthony Bihl to Board of Directors
6. Tianyin Pharmaceutical Appoints Three New Independent Board Members
7. Hiemstra Appoints Robert C. Glines as Director of Business Development
8. Tengion Appoints Jeff Randall to Board of Directors
9. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
10. BioStorage Technologies Appoints Dr. Wolfgang Hoffer as Managing Director of European Operations
11. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Post Your Comments:
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... York , November 24, 2015 ... a recent market research report released by Transparency Market ... to expand at a CAGR of 17.5% during the ... Prenatal Testing Market - Global Industry Analysis, Size, Volume, ... the global non-invasive prenatal testing market to reach a ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. , Oct. 26, 2015  Delta ID ... biometric authentication to mobile and PC devices, announced its ... smartphone, the arrows NX F-02H launched by NTT DOCOMO, ... NX F-02H is the second smartphone to include iris ... technology in ARROWS NX F-04G in May 2015, world,s ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a ... its first quarter ended September 30, 2015. ... of fiscal 2016 grew 66 percent over the comparable quarter last ... fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... for the first quarter of fiscal 2016 grew 39 percent over ...
Breaking Biology News(10 mins):